Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of CMV-specific IVIG (pH4) plus preemptive antiviral therapy after allogeneic HSCT
CTR20210906Phase 3Terminated
- Sponsor
- Chengdu Rongsheng Pharmaceutical
- Start
- May 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of immune serum globulin in cytomegalovirus disease (CMV), sponsored by Chengdu Rongsheng Pharmaceutical. Started May 2021; status: terminated.
02
Drugs
immune serum globulin
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on CTR20210906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210906.